Clinicopathological and molecular predictors of [18F]FDG-PET disease detection in HER2-positive early breast cancer: RESPONSE, a substudy of the randomized PHERGain trial. - Llombart-Cussac, Antonio; Prat, Aleix; Pérez-García, José Manuel; Mateos, José; Pascual, Tomás; Escrivà-de-Romani, Santiago; Stradella, Agostina; Ruiz-Borrego, Manuel; de las Heras, Begoña Bermejo; Keyaerts, Marleen; Galvan, Patricia; Brasó-Maristany, Fara; et al. (European Journal of Nuclear Medicine & Molecular Imaging, 2024)